FluGen
FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine candidate that addresses the most significant unmet needs in flu prevention – consistent efficacy, annual virus drift, and shedding.
Private Company
Total funding raised: $31.4M
About
FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine candidate that addresses the most significant unmet needs in flu prevention – consistent efficacy, annual virus drift, and shedding.